WuXi ATU announces the launch of TESSA™ technology to improve the scalability and accessibility of cell and gene therapies

black flat screen computer monitor

PHILADELPHIA CREAM, March 7, 2022 /PRNewswire/ — WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline Activated Self-Silent Adenovirus (TESSA™). This technology is a new state-of-the-art process for the scalable, transfection-free manufacturing of adeno-associated viruses (AAVs) at the Good Manufacturing Practices (GMP) level. Developed by OXGENE in the UKA WuXi Advanced Therapies company, TESSA™ will accelerate AAV manufacturing and dramatically reduce the manufacturing cost of cell and gene therapies, enabling global customers to deliver more accessible breakthrough therapies to patients as quickly as possible.

The AAV vector is a popular tool for delivering gene therapies in diseases such as hemophilia and Alzheimer’s disease. Efficient large-scale AAV manufacturing processes are essential to meet growing industry demands. TESSA™ vectors can address the scalability challenges of AAV production, which has important implications for expanding patient access to these new therapies.

The new data published in Nature Communication supports the benefits of this technology. He points out that in the same manufacturing volume, TESSA™ vectors produced 10 times more AAV than plasmid-based manufacturing, yielding enough material to treat ten times the number of patients.

“The TESSA™ System is a game-changer for manufacturing AAVs and advancing cell and gene therapies for the benefit of patients.” says dr. Ryan Cawood, scientific director of WuXi ATU. “By improving scalability, reducing process complexity and reducing gene therapy manufacturing costs, TESSA™ will enable our global partners to develop and deliver lifesaving gene therapies to more patients in need faster.” .

As a Contract Testing Development and Manufacturing Organization (CTDMO) operating globally, WuXi ATU’s unique business model integrates powerful testing capabilities with its therapies process development and manufacturing platforms. advances, such as TESSA™ technology for the manufacture of AAVs and stable Lenti solutions for the manufacture of lentivirals. . This allows all assay development, biosafety, viral clearance and product release testing to be performed in-house, shortening customer timelines for approval of advanced therapies.

About WuXi Advanced Therapies (WuXi ATU)

As the Advanced Therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Trial, Development, and Manufacturing Organization (CTDMO) that provides integrated platforms to transform discovery, development, testing, manufacturing and the commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs worldwide. For more information, please visit

About WuXi AppTec

As a global company with operations across Asia, Europeand North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discovery and deliver breakthrough treatments to patients. With its unique business models, WuXi AppTec’s end-to-end integrated services include CRDMO (Contract Research, Development and Manufacturing Organization) drug chemistry, biology discovery, preclinical testing and clinical research services, therapeutics cell and gene CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advanced healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2021 and its self-service platform empowers more than 5,700 employees in more than 30 countries to improve the health of those in need – and realize the vision that ” every medicine can be made and every disease can be treated.”